190 related articles for article (PubMed ID: 23342872)
1. [Management of hyperglycaemia in type 2 diabetes: a patient-centered approach].
Scheen AJ; Mathieu C
Rev Med Liege; 2012 Dec; 67(12):623-31. PubMed ID: 23342872
[TBL] [Abstract][Full Text] [Related]
2. Patient-Centered Guidelines for Geriatric Diabetes Care: Potential Missed Opportunities to Avoid Harm.
McCreedy EM; Kane RL; Gollust SE; Shippee ND; Clark KD
J Am Board Fam Med; 2018; 31(2):192-200. PubMed ID: 29535235
[TBL] [Abstract][Full Text] [Related]
3. Improving type 2 diabetes mellitus glycaemic outcomes is possible without spending more on medication: Lessons from the UK National Diabetes Audit.
Heald AH; Livingston M; Malipatil N; Becher M; Craig J; Stedman M; Fryer AA
Diabetes Obes Metab; 2018 Jan; 20(1):185-194. PubMed ID: 28730750
[TBL] [Abstract][Full Text] [Related]
4. What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus?
Zenari L; Marangoni A
Diabetes Obes Metab; 2013 Sep; 15 Suppl 2():17-25. PubMed ID: 24034516
[TBL] [Abstract][Full Text] [Related]
5. The 2018 update of the American College of Physicians glycaemic management recommendations: An invitation to continued inertia?
Morales J; Assumpcao-Morales M
Diabetes Obes Metab; 2018 Aug; 20(8):1809-1811. PubMed ID: 29658190
[TBL] [Abstract][Full Text] [Related]
6. Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010-2017.
Dennis JM; Henley WE; McGovern AP; Farmer AJ; Sattar N; Holman RR; Pearson ER; Hattersley AT; Shields BM; Jones AG;
Diabetes Obes Metab; 2019 Jul; 21(7):1576-1584. PubMed ID: 30828962
[TBL] [Abstract][Full Text] [Related]
7. [Management of type 2 diabetes: new or previous agents, how to choose?].
Halimi S
Presse Med; 2013 May; 42(5):861-70. PubMed ID: 23643613
[TBL] [Abstract][Full Text] [Related]
8. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
9. Early and intensive treatment: Glycaemic control in type 2 diabetes.
Bailey CJ
Diab Vasc Dis Res; 2006 Dec; 3(3):145-6. PubMed ID: 17160908
[No Abstract] [Full Text] [Related]
10. Analysis of English general practice level data linking medication levels, service activity and demography to levels of glycaemic control being achieved in type 2 diabetes to improve clinical practice and patient outcomes.
Heald A; Davies M; Stedman M; Livingston M; Lunt M; Fryer A; Gadsby R
BMJ Open; 2019 Sep; 9(9):e028278. PubMed ID: 31494602
[TBL] [Abstract][Full Text] [Related]
11. Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal.
Scheen AJ; Charbonnel B
Diabetes Metab; 2014 Jun; 40(3):176-85. PubMed ID: 24792220
[TBL] [Abstract][Full Text] [Related]
12. Mismatch between ADA and AGS recommendations for glycated hemoglobin targets for older adults.
Tasci I; Safer U; Naharci I; Sonmez A
Prim Care Diabetes; 2018 Apr; 12(2):192-194. PubMed ID: 29396204
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns among older patients with type 2 diabetes in the United States: a retrospective cohort study.
Fu H; Curtis BH; Schuster DP; Festa A; Kendall DM
Diabetes Technol Ther; 2014 Dec; 16(12):833-9. PubMed ID: 25068375
[TBL] [Abstract][Full Text] [Related]
14. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Inzucchi SE; Bergenstal RM; Buse JB; Diamant M; Ferrannini E; Nauck M; Peters AL; Tsapas A; Wender R; Matthews DR
Diabetologia; 2012 Jun; 55(6):1577-96. PubMed ID: 22526604
[No Abstract] [Full Text] [Related]
15. Management of the patient with advanced complications, functional decline, and persistent hyperglycemia.
Zettervall DK
Consult Pharm; 2010 Jun; 25 Suppl B():5-10. PubMed ID: 20726377
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review.
Khunti K; Gomes MB; Pocock S; Shestakova MV; Pintat S; Fenici P; Hammar N; Medina J
Diabetes Obes Metab; 2018 Feb; 20(2):427-437. PubMed ID: 28834075
[TBL] [Abstract][Full Text] [Related]
17. Optimal glycaemic control in elderly people with type 2 diabetes: what does the evidence say?
Mathur S; Zammitt NN; Frier BM
Drug Saf; 2015 Jan; 38(1):17-32. PubMed ID: 25481812
[TBL] [Abstract][Full Text] [Related]
18. Adherence to Guidelines for Inpatient Pharmacologic Management of Type 2 Diabetes in Adults and Glycemic Outcomes.
Alkhiari R; Alzayer H; Aljazeeri J; Vanniyasingam T; Punthakee Z
Can J Diabetes; 2018 Apr; 42(2):158-162. PubMed ID: 28662968
[TBL] [Abstract][Full Text] [Related]
19. Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries.
Hermans MP; Brotons C; Elisaf M; Michel G; Muls E; Nobels F;
Eur J Prev Cardiol; 2013 Dec; 20(6):1095-105. PubMed ID: 22605788
[TBL] [Abstract][Full Text] [Related]
20. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study.
Rosenstock J; Wilson C; Fleck P
Diabetes Obes Metab; 2013 Oct; 15(10):906-14. PubMed ID: 23531118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
